BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 21486216)

  • 21. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts.
    Auzenne E; Ghosh SC; Khodadadian M; Rivera B; Farquhar D; Price RE; Ravoori M; Kundra V; Freedman RS; Klostergaard J
    Neoplasia; 2007 Jun; 9(6):479-86. PubMed ID: 17603630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ICAM-1 mediated peritoneal carcinomatosis, a target for therapeutic intervention.
    Alkhamesi NA; Ziprin P; Pfistermuller K; Peck DH; Darzi AW
    Clin Exp Metastasis; 2005; 22(6):449-59. PubMed ID: 16320108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
    Folprecht G; Köhne CH; Lutz MP
    Cancer Treat Res; 2007; 134():425-40. PubMed ID: 17633071
    [No Abstract]   [Full Text] [Related]  

  • 24. Targeted intraabdominal chemotherapy for peritoneal carcinomatosis.
    Samel S; Löhr M
    Cancer Treat Res; 2007; 134():469-82. PubMed ID: 17633075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration.
    Colombo PE; Boustta M; Poujol S; Pinguet F; Rouanet P; Bressolle F; Vert M
    Eur J Pharm Sci; 2007 May; 31(1):43-52. PubMed ID: 17383164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer.
    Colombo PE; Boustta M; Poujol S; Jarlier M; Bressolle F; Teulon I; Ladjemi MZ; Pinguet F; Rouanet P; Vert M
    Gynecol Oncol; 2011 Sep; 122(3):632-40. PubMed ID: 21665252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer.
    Kim JE; Park YJ
    Int J Nanomedicine; 2017; 12():645-658. PubMed ID: 28176896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
    Gómez Portilla A; Cendoya I; Olabarría I; Martínez de Lecea C; Gómez Martínez de Lecea C; Gil A; Martín E; Muriel J; Magrach L; Romero E; Lirola A; Guede N; Moraza N; Fernández E; Kvadatze M; Valdovinos M; Larrabide I; Ruiz de Alegría N; Fernández JL; Castillo C; Rua O; Ulibarrena MA
    Rev Esp Enferm Dig; 2009 Feb; 101(2):97-102, 103-6. PubMed ID: 19335045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients.
    Gibbs P; Brown TJ; Ng R; Jennens R; Cinc E; Pho M; Michael M; Fox RM
    Chemotherapy; 2009; 55(1):49-59. PubMed ID: 19060478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of peritoneal carcinomatosis from colon cancer cell seeding using a pirarubicin solution in rats and nude mice.
    Favoulet P; Benoit L; Osmak L; Polycarpe E; Esquis P; Duvillard C; Guiu B; Rat P; Favre JP; Chauffert B
    World J Surg; 2004 May; 28(5):451-6. PubMed ID: 15085402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship Between Increased Fucosylation and Metastatic Potential in Colorectal Cancer.
    Osuga T; Takimoto R; Ono M; Hirakawa M; Yoshida M; Okagawa Y; Uemura N; Arihara Y; Sato Y; Tamura F; Sato T; Iyama S; Miyanishi K; Takada K; Hayashi T; Kobune M; Kato J
    J Natl Cancer Inst; 2016 Sep; 108(9):. PubMed ID: 27628655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, characterization, and antitumor evaluation of the albumin-SN38 conjugate.
    Yao Y; Su X; Xie Y; Wang Y; Kang T; Gou L; Yi C; Yang J
    Anticancer Drugs; 2013 Mar; 24(3):270-7. PubMed ID: 23233044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacokinetic study of the intraperitoneal administration of CPT-11 for patients with peritoneal seedings of gastric and colonic cancers].
    Maruyama M; Toukairin Y; Baba H; Kure N; Nagahama T; Ebuchi M
    Gan To Kagaku Ryoho; 2001 Oct; 28(11):1505-7. PubMed ID: 11707965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse.
    Konishi H; Takagi A; Kurita A; Kaneda N; Matsuzaki T
    BMC Cancer; 2012 Oct; 12():462. PubMed ID: 23046546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of a chemopreventive agent and paclitaxel in CD44-targeted hybrid nanoparticles for breast cancer treatment.
    Tran BN; Nguyen HT; Kim JO; Yong CS; Nguyen CN
    Arch Pharm Res; 2017 Dec; 40(12):1420-1432. PubMed ID: 29027133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Irinotecan delivery by microbubble-assisted ultrasound: in vitro validation and a pilot preclinical study.
    Escoffre JM; Novell A; Serrière S; Lecomte T; Bouakaz A
    Mol Pharm; 2013 Jul; 10(7):2667-75. PubMed ID: 23675982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
    Kawato Y; Furuta T; Aonuma M; Yasuoka M; Yokokura T; Matsumoto K
    Cancer Chemother Pharmacol; 1991; 28(3):192-8. PubMed ID: 1855276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyaluronan magnetic nanoparticle for mitoxantrone delivery toward CD44-positive cancer cells.
    Sargazi A; Shiri F; Keikha S; Majd MH
    Colloids Surf B Biointerfaces; 2018 Nov; 171():150-158. PubMed ID: 30025377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study of peritoneal metastatic xenograft model of colorectal cancer in the treatment of hyperthermic intraperitoneal chemotherapy with Raltitrexed.
    Qiu C; Li Y; Liang X; Qi Y; Chen Y; Meng X; Zheng H; Xu Y; Cai S; Cai G; Liu J
    Biomed Pharmacother; 2017 Aug; 92():149-156. PubMed ID: 28535418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
    Nanbu T; Umemura N; Ohkoshi E; Nanbu K; Sakagami H; Shimada J
    Oncol Rep; 2018 Jan; 39(1):367-375. PubMed ID: 29192320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.